2,000 Medpace Holdings, Inc. $MEDP Shares Acquired by Congress Asset Management Co.

by · The Markets Daily

Congress Asset Management Co. boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 3.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,479 shares of the company’s stock after buying an additional 2,000 shares during the quarter. Congress Asset Management Co.’s holdings in Medpace were worth $37,750,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Schulhoff & Co. Inc. boosted its position in Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Balefire LLC grew its position in Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock worth $217,000 after acquiring an additional 26 shares during the last quarter. Root Financial Partners LLC raised its position in Medpace by 34.1% in the first quarter. Root Financial Partners LLC now owns 122 shares of the company’s stock valued at $59,000 after purchasing an additional 31 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Medpace by 2.8% during the second quarter. GAMMA Investing LLC now owns 1,158 shares of the company’s stock valued at $613,000 after purchasing an additional 32 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in shares of Medpace by 0.6% during the second quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company’s stock worth $3,718,000 after purchasing an additional 40 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MEDP. Barclays set a $600.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Robert W. Baird raised their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Truist Financial upped their target price on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. UBS Group assumed coverage on shares of Medpace in a research report on Wednesday, September 30th. They issued a “neutral” rating and a $673.00 price target on the stock. Finally, Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $602.27.

Get Our Latest Report on Medpace

Medpace Trading Down 2.8%

NASDAQ MEDP traded down $17.61 on Tuesday, hitting $602.90. 219,122 shares of the company were exchanged, compared to its average volume of 330,176. The company has a market cap of $16.83 billion, a PE ratio of 35.34, a PEG ratio of 2.67 and a beta of 1.18. The stock has a fifty day moving average of $600.57 and a 200-day moving average of $522.82. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insiders Place Their Bets

In other Medpace news, CEO August Troendle sold 49,018 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total value of $30,788,695.98. Following the transaction, the chief executive officer owned 433,372 shares in the company, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders sold 336,140 shares of company stock worth $208,008,328. 20.50% of the stock is currently owned by corporate insiders.

Medpace Profile

(Free Report)

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.

Featured Articles

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).